 |
인쇄하기
취소
|
KFDA warns adverse events on clevudine
The Korea Food and Drug Administration said on April 21 it issued a caution to medical doctors and pharmacists about prescribing Levovir (clevudine) for the treatment of chronic hepatitis B (HBV) infection.
The drug agency said it has become aware of a number of spontaneous serious adverse events in patients receiving clevudine as prescribed therapy for hepatitis B in Korea.
Pharmasset, I...
The drug agency said it has become aware of a number of spontaneous serious adverse events in patients receiving clevudine as prescribed therapy for hepatitis B in Korea.
Pharmasset, I...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.